ECH1 (Enoyl-CoA Hydratase 1) is an enzyme involved in fatty acid β-oxidation, catalyzing the hydration of 2-trans-enoyl-CoA to 3-hydroxyacyl-CoA in mitochondria. It plays a critical role in energy metabolism and cellular homeostasis. Dysregulation of ECH1 has been implicated in metabolic disorders, neurodegenerative diseases, and cancer, making it a research target for understanding disease mechanisms.
ECH1 antibodies are essential tools for detecting and quantifying ECH1 protein expression in various experimental applications, including Western blotting, immunohistochemistry, and immunofluorescence. These antibodies are typically developed using immunogenic peptides or recombinant ECH1 protein fragments to ensure specificity. Validation steps, such as knockout controls or siRNA knockdown, are crucial to confirm antibody reliability.
Research utilizing ECH1 antibodies has revealed its tissue-specific expression patterns, with high levels in energy-demanding organs like the liver, heart, and kidneys. In cancer studies, altered ECH1 expression has been linked to tumor progression, metastasis, and chemoresistance, suggesting its potential as a therapeutic or diagnostic biomarker. Additionally, ECH1 antibodies aid in studying mitochondrial dysfunction in metabolic syndromes, providing insights into lipid metabolism imbalances.
Overall, ECH1 antibodies serve as pivotal reagents for exploring the enzyme’s biological roles and its implications in human diseases, bridging molecular insights to clinical applications.